Physician profile
Ruby Varghese Thomas
NPI 1477907244
$1,055.63
in general payments reported to CMS, 2019-2025
14 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $156 · 2023: $199 · 2024: $438 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $339.19 | 2023-2024 | Nalu Neurostimulation System |
| Medtronic, INC. | $335.41 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Collegium Pharmaceutical, INC. | $101.10 | 2021-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $51.43 | 2025 | Intracept |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.31 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $30.00 | 2023 | Andexxa |
| Braeburn INC. | $28.24 | 2024 | Brixadi |
| Indivior INC. | $27.55 | 2021 | |
| Sk Life Science, INC. | $26.50 | 2021 | |
| Convatec INC. | $19.17 | 2025 | |
| Xeris Pharmaceuticals, INC. | $15.91 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.58 | 2024 | Gattex |
| Abbvie INC. | $15.21 | 2022 | |
| Grt US Holding, INC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.